Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. AI Tech Top10 & U.S. High Dividend 3070 Index (AUTUD37)
3/23/2026, 12:00:00 AM
Pfizer and Valneva announced positive but mixed Phase 3 results for their Lyme disease vaccine candidate. While demonstrating over 70% efficacy, the trial missed its primary statistical endpoint. Pfizer remains confident and plans regulatory submissions.
Korean Translation
화이자와 발네바의 라임병 백신 후보물질 임상 3상 결과 발표함. 70% 이상의 효능을 보였으나 주요 통계적 평가변수 충족하지 못함. 화이자의 규제 당국 승인 신청 계획 포함함.
Related Recent Events
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
HF Sinclair Corp (DINO) · Earnings Release
Next earnings release for Q1 2026 is scheduled for May 7, 2026. A price impact of over 1% is expected.
5/7/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q1 2026 earnings release is scheduled for May 5, 2026, with analysts forecasting EPS of approximately $1.27, estimated. Medium importance is estimated as earnings reports typically drive significant price volatility, scheduled.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
First quarter 2026 earnings release and conference call scheduled.
5/5/2026, 12:00:00 AM
Palantir Technologies Inc (PLTR) · Earnings Release
Palantir's Q1 2026 earnings release, for which low importance is estimated as the market typically reacts to the actual data rather than the schedule, is scheduled.
5/4/2026, 12:00:00 AM
Reynolds Consumer Products Inc (REYN) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS of $0.24. Medium importance estimated based on historical earnings volatility; scheduled.
4/29/2026, 12:00:00 AM